Genomic analysis of the clonal origin and evolution of acute promyelocytic leukemia in a unique patient with a very late (17 years) relapse Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by infiltration of abnormal promyelocytes in the bone marrow (BM) and the presence of the balanced reciprocal translocation between the long arms of chromosomes 15 and 17, t(15;17)(q22;q12-21). 1 The resulting hybrid PML-RARa gene encodes for a fusion oncoprotein that promotes self-renewal and blocks differentiation at the promyelocyte stage.
2 APL was once the most devastating AML subtype because of its coagulopathy, fibrinolysis and rapid death due to internal bleeding. The introduction of all-transretinoic acid (ATRA), a cell differentiation inducer, has markedly improved complete remission (CR) rate and overall outcome of patients, and ATRA combined with chemotherapy has become the gold standard for APL therapy. 1, 2 Thus, the large majority of CR patients are nowadays long-term survivors and relapses are rarely observed 3 years or more after CR achievement. 2, 3 We here report a patient with classic APL who was initially successfully treated with ATRA and chemotherapy; however, after 17 years in CR she again presented with APL. A routine diagnostic work-up did not discriminate between a relapse of her previous APL, the appearance of a secondary APL or a second de novo APL. To elucidate this diagnostic dilemma and define the clonal origin, we performed array-comparative genomic hybridization (CGH) and whole-genome sequencing (WGS) of diagnostic samples from the first and second manifestations of APL and her normal blood cells in CR.
A 42-year-old woman was admitted to hospital due to fever, widespread spontaneous bruising and pronounced fatigue in April 1994 and diagnosed with APL based on blood/BM examination (Supplementary Figure S1 ) and the typical t(15;17)(q22;q12) as revealed by cytogenetic analysis. The patient achieved hematological and cytogenetic CR following induction treatment with Accepted article preview online 21 March 2014; advance online publication, 15 April 2014 ATRA and one course of cytarabine and daunorubicin. The patient then received two consolidation courses with cytarabine and daunorubicin. The patient remained in good health and was seen at annual out-patient visits until 2003. In February 2011, almost 17 years after the initial APL diagnosis, she presented at the hospital with fatigue and bruising and an APL diagnosis was subsequently made. The patient acquired CR following the induction treatment (ATRA, idarubicin and cytarabine). Two consolidation courses with the same agents followed by two additional consolidation courses with ATRA and arsenic trioxide (ATO) were then given. The patient has remained in molecular remission since April 2011. The disease history is summarized in Figure 1a .
The array-CGH analysis showed that both the initial APL sample and the second one harbored genetic aberrations. An overview of the genetic aberration profiles is shown in Figure 1b . Overlapping between these two samples is very rare, only for a gain of 7p14.1, B58 kb and a gain of 14q11.2, B484 kb. However, both of these two overlapping regions show copy number variation (CNV) in normal individuals. In addition, there were clear differences in the patterns of aberrations between these two samples-as seen most clearly on chromosomes 19 and 9. The initial APL sample showed a main cluster of discontinuous losses in chromosome 19 (p13.2-p13.11 and q13.11-q13.43), nearly up to 24 Mb, but a small proportion of APL cells harbored chromosome 19 deletion. For the second diagnostic sample, most of the chromosome 9 (p12-p11.2 and q12-q31.1) was lost, B16 Mb (Figure 1b ). There were more aberrational regions in the initial diagnostic sample than in the second one. Other conspicuous aberrations of the initial diagnostic material were loss of 3p25.1, p21.2-p21.1 (B2.2 Mb) and gain of 21q22.2.
WGS revealed two different PML/RARa gene fusions (Chr17: 38489469-Chr15:74316176 and Chr15:74316160-Chr17:38489139) in APL cells from both samples, with the first fusion being predominant in both (Figure 2a ). The fusion genes were further verified by Sanger sequencing (Figure 2a) . Although the fusion genes/breakpoints were identical, significant differences in genetic aberrations were observed between the first and second APL samples, as revealed by WGS (Figure 1b Figure S3) .
We believe that our patient documents the longest interval between diagnosis and relapse of APL described in the literature to date. 3 Genomic analyses show how APL clones evolved between the two manifestations of APL in this patient ( Figure 2b) . Likely, the patient's hematopoietic cells underwent PML-RARa gene fusion following a genetic attack, leading to the generation of abnormal ancestral or pre-leukemic clones, which is consistent with recent studies. 4 These ancestral clones did not transform into APL until the acquisition of FLT3ITD by another genetic attack. The patient obtained a CR following ATRA treatment plus chemotherapy in 1994. APL blast clones were eradicated after treatment, but the ancestral clones carrying the PML-RARa fusion gene were persistent and acquired a FLT3-D835 point mutation later. The PML-RARa/FLT3-D835 clones then contributed to the second onset of APL in 2011.
A recent study shows that mutant DNMT3 or IDH2-carrying pre-leukemic hematopoietic stem cells survive induction chemotherapy and are persistent in BM during CR, thereby providing a potential reservoir for leukemic progression. 4 It is thus evident that complete cure for AML depends on eliminating those pre-leukemic clones. Similarly, the presence of the PML-RARa fusion gene alone is not sufficient to cause APL, 5 and ancestral PML/RARa-positive clones may be resistant to anti-APL therapy, causing future relapses when a new genetic attack occurs, as seen in this patient. It has been demonstrated that ATO is capable of specifically targeting PML/RARa-positive cells, hopefully preventing APL recurrence. 1 Accordingly, the present patient was given ATRA and chemotherapy as induction and ATRA/ATO as consolidation therapy at relapse. The patient has so far remained in a molecular remission and will be remain in close molecular monitoring.
In summary, we here describe an extremely late relapse of APL and the leukemic clonal evolution. Very late relapses in APL, as seen in this unique patient, are more likely caused by a new genetic attack on existing pre-APL clones, which differs from early relapses resulting from the re-growth of original residual APL blasts. Genomic characterization of late relapses may have therapeutic implications. Trisomy 8 ( þ 8) is the most frequent numerical chromosome aberration in acute myeloid leukemia (AML), occurring in B9% of adult patients. 1 In one-third of such patients, þ 8 is the sole cytogenetic abnormality. 1 These patients are mostly classified as having an intermediate prognosis. 1, 2 The few available studies suggest that sole þ 8 AML is molecularly heterogeneous, [3] [4] [5] but the clinical impact of mutations remains to be established. Moreover, although the biologic features of sole þ 8 AML have been investigated using genome-wide gene- 6, 7 or microRNAexpression 8 analyses, these studies included small numbers of patients.
We report herein the molecular and clinical characterization of 80 adults with de novo AML and sole þ 8 enrolled on Cancer and Leukemia Group B/Alliance clinical trials. Methodological details are described in the Supplementary Information.
Ninety-four percent of the sole þ 8 AML patients harbored at least one mutation (Supplementary Figure S1) . The most frequently mutated genes were RUNX1 (32%), ASXL1 (29%), FLT3 (specifically FLT3-ITD: 29%), IDH2 (26%), DNMT3A (25%) and NPM1 (22.5%) ( Table 1) . Younger (o60 years) patients less often harbored mutations in RUNX1 (P ¼ 0.008), ASXL1 (P ¼ 0.002), IDH2 (P ¼ 0.04) and TET2 (P ¼ 0.001) than older (X60 years) patients.
We compared the mutational features of the þ 8 AML cohort with CN-AML patients, the largest and molecularly best characterized cytogenetic subset of AML.
1,2 Among younger and older patients, those with sole þ 8 more often had mutations in ASXL1 (younger, P ¼ 0.04; older, Po0.001) and RUNX1 (younger, P ¼ 0.08; older, Po0.001) and less often in NPM1 (younger and older, Po0.001) (Supplementary Table S1 ). Younger sole þ 8 patients also less frequently had TET2 (P ¼ 0.002) and CEBPA (P ¼ 0.005) mutations than CN-AML patients. Hence, particularly mutations in ASXL1 and RUNX1 associate with sole þ 8 AML. However, no single mutation was as tightly associated with þ 8 AML as reported for AML with other numeric aberrations, for example, þ 11 and MLL-PTD, 9 þ 13 and RUNX1 mutations. 10 Future studies may determine whether þ 8 favors acquisition of RUNX1 and ASXL1 mutations or whether CN-AML with such mutations is prone to the gain of þ 8.
Patients included in the outcome analyses received cytarabine/ daunorubicin-based induction and consolidation, and no allogeneic hematopoietic stem-cell transplantation in first complete remission (CR) (Supplementary Table S2 ). As in previous reports, 1 the outcomes of sole þ 8 AML patients were relatively poor; 64% achieved a CR and 5-year rates were 9% for disease-free survival (DFS) and 15% for overall survival (OS) ( Table 1) . Notably, there were no significant differences in CR rates, DFS or OS between younger and older patients (Table 1) , despite differences in treatment intensity. This is in contrast with the better outcomes of younger patients previously observed in CN-AML 2 and could be related to differences in the mutation or gene-expression patterns (described below) between the cytogenetic subsets.
To further characterize the outcome of sole þ 8 AML, we evaluated it in comparison with CN-AML and in the context of the European LeukemiaNet classification. 2 Among younger adults, sole þ 8 AML associated with worse CR rates (P ¼ 0.003), and shorter DFS (P ¼ 0.01) and OS (P ¼ 0.003) than CN-AML; among older individuals, sole þ 8 patients had only a trend for shorter DFS (P ¼ 0.09) (Supplementary Table S3 ). In the European LeukemiaNet recommendations, 2 the Intermediate-II Genetic Group consists of two subsets: patients with t(9;11)(p22;q23) and patients with cytogenetic aberrations not classified in the Favorable or Adverse Genetic Groups, which also include sole þ 8. Thus, we compared the outcome of sole þ 8 patients with that of t(9;11) patients and the remaining Intermediate-II patients (Supplementary Table S3 ). Among younger adults, sole þ 8 patients had shorter DFS (P ¼ 0.02) and OS (P ¼ 0.02) than t(9;11) patients, and worse CR rates (P ¼ 0.04) and OS (P ¼ 0.05) but no significant differences in DFS compared with the remaining Intermediate-II patients. Among older patients, there were no significant outcome differences between sole þ 8, t(9;11) and the remaining Intermediate-II patients.
It is currently unknown whether molecular markers allow risk stratification in sole þ 8 AML. Thus, we tested the prognostic significance of the various markers in multivariable models (Table 2) .
In younger patients, only BAALC expression impacted on CR attainment, with high BAALC expressers having lower odds of achieving a CR (P ¼ 0.04). FLT3-ITD status was the only variable associated with DFS; patients with FLT3-ITD had worse DFS than those without (P ¼ 0.054). Both harboring FLT3-ITD (P ¼ 0.02) and Accepted article preview online 21 March 2014; advance online publication, 15 April 2014
